Overview

Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (Geometry Mono-1)

Status:
Active, not recruiting
Trial end date:
2023-03-23
Target enrollment:
Participant gender:
Summary
A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals